MCID: SBS004
MIFTS: 49

Substance Dependence

Categories: Mental diseases

Aliases & Classifications for Substance Dependence

MalaCards integrated aliases for Substance Dependence:

Name: Substance Dependence 12 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9973
NCIt 47 C35458
SNOMED-CT 64 103326000 255338002
UMLS 69 C0439857

Summaries for Substance Dependence

Disease Ontology : 12 A substance-related disorder that involves the continued use of alcohol or other drugs despite problems related to use of the substance.

MalaCards based summary : Substance Dependence is related to personality disorder and schizophrenia. An important gene associated with Substance Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Transmission across Chemical Synapses and Peptide ligand-binding receptors. The drugs Aripiprazole and Amphetamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 72 Substance dependence also known as drug dependence is an adaptive state that develops from repeated drug... more...

Related Diseases for Substance Dependence

Diseases related to Substance Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 97)
id Related Disease Score Top Affiliating Genes
1 personality disorder 27.7 BDNF CNR1 DRD2 DRD3 MAOA OPRM1
2 schizophrenia 27.0 BDNF CNR1 DRD2 DRD3 DRD5 HTR1B
3 heroin dependence 22.9 ADH1A ADH4 BDNF CHRNA3 CHRNA5 CHRNB4
4 drug dependence 11.0
5 cyclotropia 10.8 OPRD1 OPRK1 OPRM1
6 cervicitis 10.7 OPRD1 OPRK1 OPRM1
7 cystic hygroma lethal cleft palate 10.7 CNR1 OPRM1
8 edict syndrome 10.7 CHRNA3 CHRNA5
9 contact dermatitis 10.6 DRD2 DRD5 SLC6A3
10 autoimmune disease of central nervous system 10.6 CNR1 OPRM1 POMC
11 semantic agnosia 10.5 CNR1 OPRK1 OPRM1 POMC
12 cervical adenosarcoma 10.5 CNR1 OPRK1 OPRM1 POMC
13 dementia - subcortical 10.4 CNR1 OPRM1
14 osteogenesis imperfecta, type ix 10.4 BDNF DRD2 DRD5 SLC6A3
15 simple chronic conjunctivitis 10.4 BDNF CHRNA3 CHRNA5 CNR1
16 eosinophilia-myalgia syndrome 10.3 BDNF DRD2 OPRD1 OPRM1 SLC6A3
17 active cochlear meniere's disease 10.3 BDNF POMC
18 intracranial cavernous angioma 10.3 DRD2 SLC6A3 SLC6A4
19 splenic abscess 10.3 DRD2 SLC6A3 SLC6A4
20 ornithosis 10.2 DRD2 MAOA SLC6A4
21 x-linked dominant intellectual disability-epilepsy syndrome 10.2 CNR1 OPRK1
22 uterus intravascular leiomyomatosis 10.2 MAOA OPRK1 SLC6A4
23 bladder hepatoid adenocarcinoma 10.2 DRD2 SLC6A3 SLC6A4
24 tinea pedis 10.1 MAOA SLC6A3 SLC6A4
25 angiokeratoma of mibelli 10.1 MAOA OPRK1 SLC6A4
26 anodontia 10.1 HTR1B SLC6A3 SLC6A4
27 conjunctival pigmentation 10.1 MAOA SLC6A4
28 hemorrhagic cystitis 10.0 DRD2 MAOA SLC6A3 SLC6A4
29 tongue disease 10.0 DRD2 MAOA SLC6A3 SLC6A4
30 bipolar disorder 10.0
31 adult mesenchymal chondrosarcoma 10.0 POMC SLC6A4
32 renpenning syndrome 10.0 HTR1B MAOA SLC6A4
33 intrahepatic gall duct cancer 10.0 BDNF MAOA SLC6A4
34 chronic dacryoadenitis 10.0 BDNF MAOA SLC6A4
35 asperger syndrome 10.0 DRD2 DRD3 SLC6A3
36 psychotic disorder 10.0
37 hypoglycemic coma 9.9 BDNF MAOA SLC6A4
38 vallecula cancer 9.9 MAOA POMC SLC6A4
39 postencephalitic parkinson disease 9.9 BDNF DRD2 MAOA SLC6A4
40 may-hegglin anomaly 9.9 MAOA POMC SLC6A4
41 ganglioneuroma 9.9 DRD2 DRD3 SLC6A3
42 alexithymia 9.9
43 borderline personality disorder 9.9
44 antisocial personality disorder 9.9
45 conduct disorder 9.9
46 alcohol dependence 9.9
47 placenta disease 9.9 DRD2 DRD3
48 hepatic angiomyolipoma 9.9 BDNF CNR1 SLC6A3 SLC6A4
49 carotid stenosis 9.8 DRD2 DRD5 MAOA SLC6A3 SLC6A4
50 attention deficit-hyperactivity disorder 9.8

Graphical network of the top 20 diseases related to Substance Dependence:



Diseases related to Substance Dependence

Symptoms & Phenotypes for Substance Dependence

MGI Mouse Phenotypes related to Substance Dependence:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 BDNF CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2
2 homeostasis/metabolism MP:0005376 10.13 BDNF CHRNA3 CHRNB4 CNR1 DRD2 DRD3
3 nervous system MP:0003631 10.03 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD3
4 endocrine/exocrine gland MP:0005379 10.02 BDNF DRD2 DRD5 HTR1B OPRK1 OPRM1
5 digestive/alimentary MP:0005381 10.01 BDNF CHRNA3 CHRNB4 CNR1 DRD2 DRD3
6 integument MP:0010771 9.96 BDNF CHRNB4 CNR1 DRD2 OPRD1 OPRK1
7 adipose tissue MP:0005375 9.85 CNR1 DRD2 DRD3 OPRM1 POMC
8 no phenotypic analysis MP:0003012 9.56 HTR1B OPRD1 OPRM1 POMC BDNF CHRNA3
9 taste/olfaction MP:0005394 8.92 DRD2 SLC6A3 BDNF CNR1

Drugs & Therapeutics for Substance Dependence

Drugs for Substance Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 436)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 2,Phase 3 129722-12-9 60795
2
Amphetamine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 300-62-9 5826 3007
3
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52485-79-7 40400 644073
4
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 561-27-3 5462328
5
Biperiden Approved Phase 4,Phase 3,Phase 2 514-65-8 2381
6
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
7
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
8
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 77337-76-9 71158
9
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
10
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 16590-41-3 5360515
11
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
12
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 249296-44-4 5310966
13
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1 97240-79-4 5284627
14
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 465-65-6 5284596
15
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1 106266-06-2 5073
16
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1 34841-39-9, 34911-55-2 444
17
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-99-3 4095
18
Lorazepam Approved Phase 4,Phase 2 846-49-1 3958
19
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 537-46-2 10836
20
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 75614-87-8, 51-45-6 774
21
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
22
Prazosin Approved Phase 4,Phase 3,Phase 2 19216-56-9 4893
23
Carbon monoxide Approved Phase 4,Phase 3,Phase 2 630-08-0 281
24
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
25
Methylphenidate Approved, Investigational Phase 4,Phase 2 113-45-1 4158
26
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 616-91-1 12035
27
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 60142-96-3 3446
28
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-56-6 439302 53477758
29
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
30
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 99-66-1 3121
31
Ribavirin Approved Phase 4 36791-04-5 37542
32
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
33
Disulfiram Approved Phase 4,Phase 2,Phase 1 97-77-8 3117
34
Desipramine Approved Phase 4,Phase 2 50-47-5 2995
35
Carbamazepine Approved, Investigational Phase 4,Phase 2 298-46-4 2554
36
Oxazepam Approved Phase 4 604-75-1 4616
37
Sodium oxybate Approved Phase 4 502-85-2 5360545
38
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
39
Zonisamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 68291-97-4 5734
40
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2 84057-84-1 3878
41
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 6740-88-1 3821
42
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
43
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 57-83-0 5994
44
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2,Early Phase 1 148553-50-8 5486971
45
Caffeine Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-08-2 2519
46
Choline Approved, Nutraceutical Phase 4,Phase 3,Phase 2 62-49-7 305
47 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
48
gamma-Aminobutyric acid Investigational Phase 4,Phase 2,Phase 3 56-12-2 119
49
Butyric Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 107-92-6 264
50 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1412)

id Name Status NCT ID Phase Drugs
1 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Unknown status NCT01155544 Phase 4
2 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Unknown status NCT01153490 Phase 4
3 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
4 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
5 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
6 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4 caffeine;Biperiden;Placebo
7 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
8 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
9 Trial for the Treatment of Alcohol Dependence Unknown status NCT00120601 Phase 4 Naltrexone;Acamprosate
10 Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity Unknown status NCT00664755 Phase 4 varenicline
11 Topiramate for Hospitalized Patients With Alcoholism: a 12-week Study Unknown status NCT01135602 Phase 4 Topiramate
12 Effectiveness of an E-mail Tracking Intervention Among the Continued Abstinence of Tobacco Consumption Unknown status NCT01494246 Phase 4
13 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
14 Chemical Dependency and Smoking Cessation: Patient's Views - 1 Completed NCT00051883 Phase 4
15 Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse Completed NCT00573534 Phase 4 Vyvanse
16 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
17 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
18 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
19 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
20 Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
21 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
22 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
23 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4 Buprenorphine/naloxone
24 Integrating Buprenorphine Into the SFGH AIDS Program Completed NCT00263458 Phase 4
25 Abilify Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
26 Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse Completed NCT00223197 Phase 4 Pregnenolone
27 Substance Dependent Teens - Impact of Treating Depression Study 1 - 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
28 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9 Completed NCT00015275 Phase 4
29 Brain Changes in Stimulant Dependent Subjects - 8 Completed NCT00000343 Phase 4
30 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
31 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
32 Quetiapine for Cocaine Use and Cravings Completed NCT00232336 Phase 4 quetiapine
33 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
34 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
35 Electronic Cigarettes in Daily Dependent Smokers Completed NCT02108626 Phase 4 Nicotine;Placebo
36 Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI) Completed NCT00453609 Phase 4 long-lasting injectable naltrexone
37 Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed NCT00000321 Phase 4 Desipramine
38 Pharmacotherapy and Intensive Treatment - 2 Completed NCT00000218 Phase 4 Carbamazepine
39 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
40 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
41 Smoking Cessation in Alcoholism Treatment Completed NCT00000454 Phase 4 nicotine replacement patch
42 Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") Completed NCT00955162 Phase 4 Buprenorphine (Subutex);Buprenorphine/naloxone (Suboxone)
43 Creatine as a Treatment Option for Depression in Methamphetamine Using Females Completed NCT01514630 Phase 4 Creatine monohydrate
44 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Drug;Placebo
45 The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia Completed NCT00495352 Phase 4 Hihg-doseNRT, Low-dose NRT, bupropion
46 Naltrexone for Heavy Drinking in Young Adults Completed NCT00568958 Phase 4 naltrexone;placebo naltrexone
47 Study of Aripiprazole in Subjects With Alcoholism Completed NCT00082199 Phase 4 Aripiprazole;Placebo
48 Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome Completed NCT02090504 Phase 4 Sodium Oxybate (SMO);Oxazepam
49 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
50 Buspirone Treatment for Marijuana Dependence Completed NCT00875836 Phase 4 Buspirone;Placebo

Search NIH Clinical Center for Substance Dependence

Genetic Tests for Substance Dependence

Anatomical Context for Substance Dependence

MalaCards organs/tissues related to Substance Dependence:

39
Brain, Testes, Liver, Eye, Pituitary, Spinal Cord, Heart

Publications for Substance Dependence

Articles related to Substance Dependence:

(show top 50) (show all 389)
id Title Authors Year
1
Depression and severity of substance dependence among heroin dependent patients with ADHD symptoms. ( 27997065 )
2017
2
The effects of patient and physician characteristics on early outpatient satisfaction with substance dependence care: results of the SUBUSQOL study. ( 28507432 )
2017
3
Lifetime and recent alcohol use and bone mineral density in adults with HIV infection and substance dependence. ( 28445303 )
2017
4
Polypharmacy and risk of non-fatal overdose for patients with HIV infection and substance dependence. ( 28847449 )
2017
5
Substance dependence among those without symptoms of substance abuse in the World Mental Health Survey. ( 28211594 )
2017
6
Patient experiences questionnaire for interdisciplinary treatment for substance dependence (PEQ-ITSD): reliability and validity following a national survey in Norway. ( 28219361 )
2017
7
Behavioral approach and orbitofrontal cortical activity during decision-making in substance dependence. ( 28934666 )
2017
8
Lifetime history of traumatic events in a young adult Mexican American sample: Relation to substance dependence, affective disorder, acculturation stress, and PTSD. ( 27569652 )
2016
9
Attention deficit hyperactivity disorder symptoms, type of offending and recidivism in a prison population: The role of substance dependence. ( 27455899 )
2016
10
Disturbing sleep and sleepfulness during recovery from substance dependence in residential rehabilitation settings. ( 27917494 )
2016
11
Comorbid depression, antisocial personality, and substance dependence: Relationship with delay discounting. ( 26846198 )
2016
12
Which adolescents develop persistent substance dependence in adulthood? Using population-representative longitudinal data to inform universal risk assessment. ( 26620720 )
2016
13
A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care. ( 27733137 )
2016
14
Mentalization-based therapy adherence and competence stimulates in-session mentalization in psychotherapy for borderline personality disorder with co-morbid substance dependence. ( 27093128 )
2016
15
Does Emotion Dysregulation Mediate the Relationship between Early Maltreatment and Later Substance Dependence? Findings of the CANSAS Study. ( 27438781 )
2016
16
Mindfulness-Oriented Recovery Enhancement versus CBT for co-occurring substance dependence, traumatic stress, and psychiatric disorders: Proximal outcomes from a pragmatic randomized trial. ( 26701171 )
2016
17
Use of Family CAGE-AID questionnaire to screen the family members for diagnosis of substance dependence. ( 27748296 )
2016
18
An association study revealed substantial effects of dominance, epistasis and substance dependence co-morbidity on alcohol dependence symptom count. ( 27151647 )
2016
19
The Positive and Negative Syndrome Scale (PANSS): A Three-Factor Model of Psychopathology in Marginally Housed Persons with Substance Dependence and Psychiatric Illness. ( 26999280 )
2016
20
Integrated Exposure-Based Therapy for Co-Occurring Post Traumatic Stress Disorder (PTSD) and Substance Dependence: Predictors of Change in PTSD Symptom Severity. ( 27854264 )
2016
21
Associations between compulsive buying and substance dependence/abuse, major depressive episodes, and generalized anxiety disorder among men and women. ( 27215919 )
2016
22
Alcohol-Dependent Subjects Show Different Personality Traits Compared With Subjects With Multiple Substance Dependence: Preliminary Data. ( 26079976 )
2015
23
Impaired Decision-Making, Higher Impulsivity, and Drug Severity in Substance Dependence and Pathological Gambling. ( 25918968 )
2015
24
Epidemiological Studies of Substance Dependence and Abuse in Adults. ( 26417548 )
2015
25
Investigating the factor structure of the Illness Perception Questionnaire-revised for substance dependence among injecting drug users in China. ( 25649986 )
2015
26
A Pilot Study of Seeking Safety in a Sample of German Women Outpatients with Substance Dependence and Posttraumatic Stress Disorder. ( 26514284 )
2015
27
The prescription of addiction medications after implementation of chronic care management for substance dependence in primary care. ( 25524751 )
2015
28
Medical diagnoses associated with substance dependence among inpatients at a large urban hospital. ( 26107402 )
2015
29
Dissecting ancestry genomic background in substance dependence genome-wide association studies. ( 26267224 )
2015
30
Psychoactive Substance Dependence: A Dentist's Challenge. ( 26556258 )
2015
31
Posttraumatic stress disorder symptoms and risky behaviors among trauma-exposed inpatients with substance dependence: The influence of negative and positive urgency. ( 26278196 )
2015
32
Metacognitive and Meta-Emotional Styles in Patients With Alcohol and the Other Substance Dependence. ( 26495260 )
2015
33
Comparing Sensory Information Processing and Alexithymia between People with Substance Dependency and Normal. ( 26885354 )
2015
34
Women with comorbid substance dependence and psychiatric disorders in Sweden: a longitudinal study of hospital care utilization and costs. ( 26048811 )
2015
35
Temperament and character dimensions assessed in general population, in individuals with psychoactive substance dependence and in young male conscripts. ( 25687735 )
2015
36
Effectiveness of Computer-Assisted Therapy for Substance Dependence Using Breaking Free Online: Subgroup Analyses of a Heterogeneous Sample of Service Users. ( 26543918 )
2015
37
Engagement and substance dependence in a primary care-based addiction treatment program for people infected with HIV and people at high-risk for HIV infection. ( 26298399 )
2015
38
Emergency department use and hospitalizations among homeless adults with substance dependence and mental disorders. ( 26242968 )
2015
39
The advantages and barriers in the implementation of a substance dependence treatment information system (SDTIS). ( 26941816 )
2015
40
A study of the substance dependence effect of the ethanolic extract and iridoid-rich fraction from Valeriana jatamansi Jones in mice. ( 26600719 )
2015
41
Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. ( 26392368 )
2015
42
Reward salience and risk aversion underlie differential ACC activity in substance dependence. ( 26106528 )
2015
43
Relationship between drug dreams, affect, and craving during treatment for substance dependence. ( 25700139 )
2015
44
The Comorbid and Individual Impacts of Maternal Depression and Substance Dependence on Parenting and Child Behavior Problems. ( 26478656 )
2015
45
Personal Network Recovery Enablers and Relapse Risks for Women With Substance Dependence. ( 25231945 )
2014
46
Recovery of neurocognitive functions following sustained abstinence after substance dependence and implications for treatment. ( 25240109 )
2014
47
Emotional and social loneliness in individuals with and without substance dependence disorder. ( 25632385 )
2014
48
A longitudinal study of childhood ADHD and substance dependence disorders in early adulthood. ( 24731117 )
2014
49
Marijuana use and achievement of abstinence from alcohol and other drugs among people with substance dependence: a prospective cohort study. ( 24986785 )
2014
50
Chronic Care Management for Substance Dependence in Primary Care Among Patients With Co-Occurring Disorders. ( 25219686 )
2014

Variations for Substance Dependence

Expression for Substance Dependence

Search GEO for disease gene expression data for Substance Dependence.

Pathways for Substance Dependence

Pathways related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 CHRNA3 CHRNA5 CHRNB4 MAOA SLC6A3 SLC6A4
2
Show member pathways
12.67 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD3
3
Show member pathways
12.17 CHRNA3 CHRNB4 DRD2 DRD3 DRD5 MAOA
4
Show member pathways
12.13 BDNF DRD2 DRD5 HTR1B
5 12.01 BDNF CHRNB4 MAOA SLC6A4
6
Show member pathways
11.83 BDNF DRD2 MAOA SLC6A3
7 11.79 HTR1B MAOA SLC6A4
8
Show member pathways
11.79 DRD2 DRD3 DRD5 HTR1B
9 11.76 MAOA OPRD1 OPRM1 POMC
10
Show member pathways
11.59 ADH1A ADH4 MAOA
11
Show member pathways
11.57 CHRNA3 CHRNA5 DRD2 DRD3
12
Show member pathways
11.29 MAOA SLC6A3 SLC6A4
13 10.99 HTR1B MAOA SLC6A4
14
Show member pathways
10.93 MAOA SLC6A3 SLC6A4
15 10.73 DRD2 DRD3 DRD5
16
Show member pathways
10.69 ADH4 MAOA

GO Terms for Substance Dependence

Cellular components related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.78 CNR1 DRD2 OPRM1 SLC6A3
2 postsynaptic membrane GO:0045211 9.73 CHRNA3 CHRNA5 CHRNB4 OPRD1
3 perikaryon GO:0043204 9.67 DRD2 OPRK1 OPRM1
4 membrane raft GO:0045121 9.65 CNR1 OPRD1 OPRM1 SLC6A3 SLC6A4
5 axon terminus GO:0043679 9.58 DRD2 OPRD1 OPRK1
6 dendrite membrane GO:0032590 9.46 OPRD1 OPRM1
7 neuron projection GO:0043005 9.43 CHRNB4 OPRD1 OPRK1 OPRM1 SLC6A3 SLC6A4
8 integral component of plasma membrane GO:0005887 9.36 CHRNB4 CNR1 DRD2 DRD3 DRD5 HTR1B
9 acetylcholine-gated channel complex GO:0005892 9.33 CHRNA3 CHRNA5 CHRNB4
10 plasma membrane GO:0005886 10.21 ADH1A CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2
11 integral component of membrane GO:0016021 10.2 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD3

Biological processes related to Substance Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
id Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.92 OPRD1 OPRK1 OPRM1 POMC
2 chemical synaptic transmission GO:0007268 9.91 CHRNA5 DRD5 HTR1B OPRD1 OPRK1 OPRM1
3 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.86 OPRD1 OPRK1 OPRM1
4 excitatory postsynaptic potential GO:0060079 9.86 CHRNA3 CHRNA5 CHRNB4 OPRM1
5 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.85 OPRD1 OPRK1 OPRM1
6 negative regulation of adenylate cyclase activity GO:0007194 9.84 DRD2 DRD3 OPRM1
7 sensory perception of pain GO:0019233 9.84 CNR1 OPRD1 OPRK1 OPRM1
8 regulation of sensory perception of pain GO:0051930 9.81 OPRD1 OPRK1 OPRM1
9 eating behavior GO:0042755 9.81 OPRD1 OPRK1 OPRM1
10 synaptic transmission, cholinergic GO:0007271 9.8 CHRNA3 CHRNA5 CHRNB4
11 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.8 CNR1 HTR1B OPRD1 OPRM1
12 response to amphetamine GO:0001975 9.79 DRD2 DRD3 DRD5
13 regulation of dopamine secretion GO:0014059 9.77 DRD2 DRD3 HTR1B
14 behavioral response to cocaine GO:0048148 9.76 DRD2 DRD3 OPRK1
15 synaptic transmission, dopaminergic GO:0001963 9.74 DRD2 DRD3 DRD5
16 regulation of smooth muscle contraction GO:0006940 9.73 CHRNA3 CHRNB4
17 vasoconstriction GO:0042310 9.73 HTR1B SLC6A4
18 negative regulation of protein secretion GO:0050709 9.73 DRD2 DRD3
19 estrous cycle GO:0044849 9.72 OPRK1 OPRM1
20 negative regulation of cAMP biosynthetic process GO:0030818 9.72 HTR1B OPRM1
21 behavioral response to ethanol GO:0048149 9.72 DRD2 OPRM1
22 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.72 DRD2 HTR1B
23 dopamine metabolic process GO:0042417 9.72 DRD2 DRD3
24 prepulse inhibition GO:0060134 9.72 DRD2 DRD3 SLC6A3
25 response to nicotine GO:0035094 9.72 CHRNA5 CHRNB4 CNR1 DRD2 SLC6A3
26 neurotransmitter biosynthetic process GO:0042136 9.71 SLC6A3 SLC6A4
27 sensory perception GO:0007600 9.71 OPRK1 OPRM1
28 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.71 DRD2 DRD5
29 ammonium transmembrane transport GO:0072488 9.71 SLC6A3 SLC6A4
30 positive regulation of renal sodium excretion GO:0035815 9.71 DRD2 DRD3
31 negative regulation of blood pressure GO:0045776 9.71 CNR1 DRD2 DRD3 DRD5
32 regulation of synaptic transmission, GABAergic GO:0032228 9.7 CNR1 DRD2
33 ethanol oxidation GO:0006069 9.7 ADH1A ADH4
34 behavior GO:0007610 9.7 HTR1B OPRK1
35 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.7 DRD2 DRD3
36 G-protein coupled receptor internalization GO:0002031 9.7 DRD2 DRD3 HTR1B
37 response to ethanol GO:0045471 9.7 CNR1 DRD2 DRD3 HTR1B OPRK1 OPRM1
38 adenohypophysis development GO:0021984 9.69 DRD2 SLC6A3
39 monoamine transport GO:0015844 9.69 SLC6A3 SLC6A4
40 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.69 DRD3 DRD5 OPRM1
41 dopamine catabolic process GO:0042420 9.68 MAOA SLC6A3
42 dopamine uptake involved in synaptic transmission GO:0051583 9.68 SLC6A3 SLC6A4
43 alcohol metabolic process GO:0006066 9.68 ADH1A ADH4
44 regulation of cAMP metabolic process GO:0030814 9.68 DRD2 DRD3
45 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.67 DRD2 DRD3
46 negative regulation of dopamine secretion GO:0033602 9.66 CNR1 DRD2
47 negative regulation of dopamine receptor signaling pathway GO:0060160 9.65 DRD2 DRD3
48 acid secretion GO:0046717 9.65 DRD2 DRD3
49 synaptic transmission involved in micturition GO:0060084 9.65 CHRNA3 CHRNB4
50 behavioral response to nicotine GO:0035095 9.65 CHRNA3 CHRNA5 CHRNB4

Molecular functions related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.8 CNR1 DRD2 DRD3 DRD5 HTR1B OPRD1
2 extracellular ligand-gated ion channel activity GO:0005230 9.7 CHRNA3 CHRNA5 CHRNB4
3 ligand-gated ion channel activity GO:0015276 9.69 CHRNA3 CHRNA5 CHRNB4
4 neuropeptide binding GO:0042923 9.65 OPRD1 OPRK1 OPRM1
5 acetylcholine binding GO:0042166 9.63 CHRNA3 CHRNA5 CHRNB4
6 acetylcholine-gated cation-selective channel activity GO:0022848 9.61 CHRNA3 CHRNA5 CHRNB4
7 retinol dehydrogenase activity GO:0004745 9.58 ADH1A ADH4
8 neurotransmitter:sodium symporter activity GO:0005328 9.58 SLC6A3 SLC6A4
9 alcohol dehydrogenase (NAD) activity GO:0004022 9.57 ADH1A ADH4
10 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.56 DRD2 DRD3
11 monoamine transmembrane transporter activity GO:0008504 9.55 SLC6A3 SLC6A4
12 alcohol dehydrogenase activity, zinc-dependent GO:0004024 9.54 ADH1A ADH4
13 acetylcholine receptor activity GO:0015464 9.54 CHRNA3 CHRNA5 CHRNB4
14 opioid receptor activity GO:0004985 9.5 OPRD1 OPRK1 OPRM1
15 dopamine:sodium symporter activity GO:0005330 9.49 SLC6A3 SLC6A4
16 dopamine neurotransmitter receptor activity GO:0004952 9.33 DRD2 DRD3 DRD5
17 dopamine binding GO:0035240 9.26 DRD2 DRD3 DRD5 SLC6A3
18 drug binding GO:0008144 9.1 CHRNB4 CNR1 DRD2 DRD3 HTR1B SLC6A3
19 G-protein coupled receptor activity GO:0004930 10.01 CNR1 DRD2 DRD3 DRD5 HTR1B OPRD1

Sources for Substance Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....